Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
about
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerGonadotropin-releasing hormone: an update review of the antagonists versus agonists.Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteinsCabazitaxel: filling one of the gaps in the treatment of prostate cancer.A hexane fraction of guava Leaves (Psidium guajava L.) induces anticancer activity by suppressing AKT/mammalian target of rapamycin/ribosomal p70 S6 kinase in human prostate cancer cellsDisease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinChemotherapy for older patients with prostate cancer.Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.Implications of insulin-like growth factor-I for prostate cancer therapies.The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trialsKnockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.Antitumour effect of electrochemotherapy with bleomycin on human prostate cancer xenograft.d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis.Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers.The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs.The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.Multifunctional nanoparticles for prostate cancer therapy
P2860
Q33374219-5B489C62-BDCE-4097-9F74-1E85FC67CFD8Q33813626-BFA52D2B-204B-4A3E-B1B9-E14723335FD2Q34636636-628EFD11-3711-4AE7-9596-55D2916E0C97Q34943321-57807E30-8303-462C-8751-75D4BC555872Q34985562-F2A73E17-BC48-4218-BA84-31DCD2750F73Q35264079-C3980387-AA25-4619-B970-D70D011C45F9Q35591498-8F824C45-E376-438D-9390-3F3B76CC42A6Q35765678-D7968796-62B6-4EF3-A412-028FDB152F05Q35979551-F2624B55-2FD7-4699-9E5C-CDC61E890137Q36596741-A594777C-674A-4B88-AF09-E54DF02ED879Q36913771-6F577FA6-2533-423B-AE7B-34E7758B0771Q37221646-9ADB99B1-8A9C-4D56-A115-E800AB0B77C8Q37381766-DB65738B-6102-4A53-87EF-1011B6209704Q38207448-A3D9713E-53FA-4D1C-BEE4-C40A4ED2171DQ38691255-A555F51B-D357-4999-9753-1B115B6EED95Q38961908-B0F50FC4-A1C3-41E1-9D73-B0EA753B1721Q39791929-64E71E53-233B-4606-A2CC-AA3455EFEC3DQ39940476-32391B57-670C-45EC-AB0E-FDB72540AB4DQ39972973-B047731F-15A9-4BA6-86EF-FA25C884B29DQ41292697-552562D6-8FAD-41FC-928D-4C3CC143CE4FQ42751429-BB87119B-0254-4022-A101-332E57B60FE9Q45990602-DCCBC7D9-4BA5-4DAE-8139-078855DD8204Q51452538-09BE3B51-F5F1-46C4-BB51-E22305585B83Q53156735-FA2F2518-77D0-4A94-8484-938EE7B19B0BQ57142675-7BE5EF4D-64D0-4901-9DA6-B3E9B5FB6465
P2860
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@ast
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@en
type
label
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@ast
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@en
prefLabel
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@ast
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@en
P2860
P1433
P1476
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
@en
P2093
Daniel Petrylak
P2860
P356
10.1111/J.1464-410X.2005.05946.X
P478
96 Suppl 2
P577
2005-12-01T00:00:00Z